The huge increase in authorised shares isn’t “housekeeping” at all it’s runway protection. NWBO clearly expects to need funding well into 2026 because the CMC expansion with Flaskworks/Eden is still ongoing, and its unknown how long that will take.
If manual manufacturing were sufficient, the MHRA review would’ve been finished long ago. Manual is already validated and licensed, but it’s far too expensive and labour-intensive to meet NICE cost-effectiveness, and thats what NWBO learned the last 2 years. So automation has to be part of the package and that's why they added the new CMC to the application in 2024. Flaskworks requires new validation work, comparability, QA/QC integration, unifying Advent and NWBO under one manufacturing entity, additional equipment/facility work and more MHRA interactions. All of that costs money and takes time.
That’s why the A/S increase is almost 1 billion shares it’s not routine. It’s simply NWBO preparing for a longer CMC timeline and securing enough runway to survive until Flaskworks is accepted. Im now at Oct 2026 for approval for a UK-wide regulatory framework for autologous dendritic-cell (DC) vaccines + Flaskworks + ofcourse GBM n and r with by that time at least 2 billion O/S if not more
If NWBO keeps doing zero PR and refuses to explain where they actually stand in the MHRA process, the share price will keep sliding. At 20–25 cents, even 900 million extra authorised shares won’t be enough to fund them. The greedy pigs are also ignoring the true-up deal, which only adds more pressure. I mean its outrageous they are rewarding themselves so heavily without much to show for no market cap increase no approval hardly any PR, nothing. Insane and sickening
So yes the A/S increase is simply NWBO giving themselves enough room to survive a long CMC timeline, but unless they communicate properly, the dilution capacity won’t last.
Market Data 
Markets 
AI
